What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Asthma
- Disease
Elisabeth H. Bel focuses on Asthma, Immunology, Internal medicine, Exhaled nitric oxide and Physical therapy.
Her study in Asthma focuses on Anti-asthmatic Agent in particular.
The various areas that she examines in her Immunology study include Airway obstruction, Airway, Sputum Cytology and Cohort.
Her Internal medicine research also works with subjects such as
- Gastroenterology, which have a strong connection to Eosinophilia and Reslizumab,
- Surgery, which have a strong connection to Family medicine.
Her study in Exhaled nitric oxide is interdisciplinary in nature, drawing from both Eosinophil, Placebo-controlled study and Pathology.
Her Physical therapy research includes themes of Refractory asthma and Intensive care medicine.
Her most cited work include:
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma (1799 citations)
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma (815 citations)
- Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. (422 citations)
What are the main themes of her work throughout her whole career to date?
Elisabeth H. Bel spends much of her time researching Asthma, Internal medicine, Immunology, Intensive care medicine and COPD.
She has researched Asthma in several fields, including Physical therapy, Disease and Pediatrics.
Her work on Mepolizumab, Corticosteroid and Cohort as part of general Internal medicine research is often related to In patient, thus linking different fields of science.
Her Immunology research is multidisciplinary, relying on both Fibrinolysis, Airway and Eosinophilic.
Her studies deal with areas such as Pulmonary disease, Severity of illness and Respiratory system as well as Intensive care medicine.
Elisabeth H. Bel interconnects Observational study and Asthma Control Questionnaire in the investigation of issues within COPD.
She most often published in these fields:
- Asthma (68.62%)
- Internal medicine (41.84%)
- Immunology (29.29%)
What were the highlights of her more recent work (between 2017-2021)?
- Asthma (68.62%)
- Internal medicine (41.84%)
- Mepolizumab (10.04%)
In recent papers she was focusing on the following fields of study:
Her scientific interests lie mostly in Asthma, Internal medicine, Mepolizumab, Severe asthma and COPD.
Her Asthma research entails a greater understanding of Immunology.
Her Internal medicine study deals with Gastroenterology intersecting with Nasal polyps, Exhaled nitric oxide and Peripheral blood.
In her work, Long term safety is strongly intertwined with Eosinophilic asthma, which is a subfield of Mepolizumab.
She combines subjects such as Airway inflammation, Clinical research, Randomized controlled trial and Asthma Control Questionnaire with her study of Severe asthma.
Her research in the fields of Obstructive lung disease overlaps with other disciplines such as Novelty.
Between 2017 and 2021, her most popular works were:
- Pathway discovery using transcriptomic profiles in adult-onset severe asthma (59 citations)
- Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology (49 citations)
- Predictors of accelerated decline in lung function in adult-onset asthma (30 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Asthma
- Disease
Elisabeth H. Bel spends much of her time researching Asthma, Internal medicine, Immunology, Intensive care medicine and Exacerbation.
She studies Exhaled nitric oxide which is a part of Asthma.
Her research links Gastroenterology with Internal medicine.
Her research investigates the connection with Intensive care medicine and areas like COPD which intersect with concerns in Disease burden.
As a part of the same scientific study, she usually deals with the Exacerbation, concentrating on Emergency department and frequently concerns with Single-nucleotide polymorphism.
In her study, Prednisone is strongly linked to Placebo, which falls under the umbrella field of Benralizumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
